Shots:

• InxMed to sponsor the trial while Merck & Co (MSD outside the United States and Canada) will provide pembrolizumab for evaluation in the trial  
• The focus of the collaboration is to evaluate the combination of InxMed’s IN10018 plus Merck’s pembrolizumab in patients with pancreatic cancer
• IN10018 (formerly BI853520) is an investigational selective ATP-competitive focal adhesion kinase (FAK) inhibitor is under clinical development in the US and China and has shown safety & efficacy results against tumors. Keytruda (pembrolizumab) is an anti-PD-1 therapy that blocks interaction between PD-1 and its ligands

Click here to read full press release/ article

Ref: Globenewswire | Image: Merck